Celcuity Inc.

10/10/2022 | Press release | Archived content

Phase II study of trastuzumab biosimilar (Herzuma®) plus gedatolisib in patients with HER 2 positive metastatic breast cancer who progressed after 2 or more HER 2 directed[...]